ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
Prostate Cancer: Can Biomarkers Make a Treatment Difference?
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="CoastWatcher" data-source="post: 78937" data-attributes="member: 2624"><p>Many men, far too many, will be diagnosed with prostate cancer. At this point in time, there are four variables that determine treatment response: patient age, tumour size, pre-treatment PSA level, and Gleason score. Most urologists will admit that these are (at best) imperfect guides for physician and patient both. Researchers are currently looking at six, prognostic biomarkers that it is hoped will identify those patients at risk for aggressive prostate cancer, or the recurrence of prostate cancer, following treatment. </p><p></p><p>A study in France analyzed all available data for these biomarkers: PHI, 4Kscore, MiPS, GPS, Prolaris, Decipher. Would these biomarkers help doctors know who, when diagnosed with prostate cancer, could best be served by:</p><p></p><ul> <li data-xf-list-type="ul">A first or second biopsy</li> <li data-xf-list-type="ul">Active surveillance/watchful waiting</li> <li data-xf-list-type="ul">Radical prostatectomy</li> <li data-xf-list-type="ul">Adjuvant treatment</li> </ul><p></p><p>Two of the biomarkers, PHI and 4Kscore, had the highest level of evidence for predicting aggressive prostate cancer. The other four showed potential for helping guide clinical decision making, but call for greater study. </p><p></p><p></p><p>We continue to see that progress in the battle against prostate cancer may be steady, but is still very slow.</p><p></p><p></p><p><a href="https://www.ncbi.nlm.nih.gov/pubmed/28753865" target="_blank">https://www.ncbi.nlm.nih.gov/pubmed/28753865</a></p><p><a href="https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/97751-prognostic-biomarkers-used-for-localised-prostate-cancer-management-a-systematic-review.html" target="_blank">https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/97751-prognostic-biomarkers-used-for-localised-prostate-cancer-management-a-systematic-review.html</a></p></blockquote><p></p>
[QUOTE="CoastWatcher, post: 78937, member: 2624"] Many men, far too many, will be diagnosed with prostate cancer. At this point in time, there are four variables that determine treatment response: patient age, tumour size, pre-treatment PSA level, and Gleason score. Most urologists will admit that these are (at best) imperfect guides for physician and patient both. Researchers are currently looking at six, prognostic biomarkers that it is hoped will identify those patients at risk for aggressive prostate cancer, or the recurrence of prostate cancer, following treatment. A study in France analyzed all available data for these biomarkers: PHI, 4Kscore, MiPS, GPS, Prolaris, Decipher. Would these biomarkers help doctors know who, when diagnosed with prostate cancer, could best be served by: [LIST] [*]A first or second biopsy [*]Active surveillance/watchful waiting [*]Radical prostatectomy [*]Adjuvant treatment [/LIST] Two of the biomarkers, PHI and 4Kscore, had the highest level of evidence for predicting aggressive prostate cancer. The other four showed potential for helping guide clinical decision making, but call for greater study. We continue to see that progress in the battle against prostate cancer may be steady, but is still very slow. [URL]https://www.ncbi.nlm.nih.gov/pubmed/28753865[/URL] [URL]https://www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/97751-prognostic-biomarkers-used-for-localised-prostate-cancer-management-a-systematic-review.html[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
Prostate Cancer: Can Biomarkers Make a Treatment Difference?
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top